Related Experiment Videos
[Cardiovascular effects of SERM]
Masahide Ohmichi1, Jun Kawagoe, Akiko Abe
1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine.
Clinical Calcium
|December 4, 2004
Summary
Raloxifene, a selective estrogen receptor modulator, promotes nitric oxide release in blood vessels and inhibits smooth muscle cell proliferation. These findings suggest cardiovascular benefits, pending large-scale trial results.
Area of Science:
- Cardiovascular Science
- Pharmacology
- Molecular Biology
Background:
- Raloxifene exhibits estrogenic effects on the cardiovascular system.
- Clinical and basic studies indicate raloxifene's role in nitric oxide (NO) synthesis and release in vascular endothelium.
- Basic research suggests raloxifene attenuates platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell proliferation.
Purpose of the Study:
- To investigate the cardiovascular effects of raloxifene.
- To elucidate the mechanisms by which raloxifene influences vascular function.
- To evaluate the potential of raloxifene in cardiovascular health.
Main Methods:
- Review of clinical and basic scientific studies on raloxifene's vascular effects.
- Analysis of raloxifene's impact on nitric oxide synthesis and release.
- Examination of raloxifene's effects on vascular smooth muscle cell proliferation, apoptosis, and cell cycle arrest.
Main Results:
- Raloxifene induces nitric oxide synthesis and release in vascular endothelium.
- Raloxifene attenuates PDGF-induced vascular smooth muscle cell proliferation.
- Mechanisms include induction of apoptosis and cell cycle arrest in smooth muscle cells.
Conclusions:
- Raloxifene demonstrates beneficial effects on the cardiovascular system through mechanisms involving nitric oxide and vascular smooth muscle regulation.
- Ongoing large-scale randomized trials, such as Raloxifene Use of The Heart, are crucial for confirming these cardiovascular benefits in clinical practice.